Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
“In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.
- “In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.
- The IND is planned for the second quarter of 2024, with an initial focus in non-small cell lung cancer.
- The Company is conducting preclinical work to further explore the opportunity and expects data in the second quarter of 2024.
- Foghorn is presenting new preclinical data for its CBP and EP300 selective degrader programs at the 2024 AACR Annual Meeting, April 5-10, 2024.